Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT14 conditioning for allo-SCT in AML (≥40–<65 years)
2024-520326-11-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute myeloid leukemia (AML), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: 1-year leukemia-free survival after allo-SCT. Planned start Jan 2025; status: authorised.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-520326-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520326-11-00.